Expertise in
9
conditions

Dr. Anca D. Askanase

Rheumatology
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
Offers Telehealth
36 Years of Experience
Expertise in
9
conditions
Trustees Of Columbia University In The City Of New York
161 Fort Washington Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anca Askanase is a Rheumatologist in New York, New York. Dr. Askanase has been practicing medicine for over 36 years is highly rated in 9 conditions, according to our data. Her top areas of expertise are Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), and Cutaneous Lupus Erythematosus (CLE).

Her clinical research consists of co-authoring 155 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
1989
Specialties
Rheumatology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
161 Fort Washington Ave, New York, NY 10032
Other Locations
TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
622 W 168th St, New York, NY 10032

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Open-label Prospective Randomized Study to Determine the Efficacy and Safety of Two Dosing Regimens of ACTHar in the Treatment of Proliferative Lupus Nephritis.
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: CellCept, ACTHar Gel
Study Phase: Phase 4
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Chloroquine (CQ) Prophylaxis for Health Care Workers at Risk for COVID
Enrollment Status: Terminated
Publish Date: February 27, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Enrollment Status: Completed
Publish Date: November 18, 2022
Intervention Type: Drug
Study Drug: JBT-101
Study Phase: Phase 2
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis (ITN055AI)
Enrollment Status: Completed
Publish Date: December 01, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
View 5 Less Clinical Trials

155 Total Publications

Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.
Prospective SARS-CoV-2 Booster Vaccination in Immunosuppressant-Treated Systemic Autoimmune Disease Patients in a Randomized Controlled Trial.
Journal: medRxiv : the preprint server for health sciences
Published: April 08, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Robert F. Spiera
Rheumatology
Expertise in
18
conditions
Dr. Robert F. Spiera
Rheumatology
1088 Park Ave, 
New York, NY 
 (4.1 mi)
Languages Spoken:
English
See accepted insurances

Robert Spiera is a Rheumatologist in New York, New York. Dr. Spiera is highly rated in 18 conditions, according to our data. His top areas of expertise are Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica.

Expertise in
19
conditions
Dr. Lindsay S. Lally
Rheumatology
Expertise in
19
conditions
Dr. Lindsay S. Lally
Rheumatology

New York Society For The Relief Of Ruptured And Crippled Maintaining

535 E 70th St, 
New York, NY 
 (5.2 mi)
212-774-7598
Experience:
17+ years
Languages Spoken:
English
Offers Telehealth

Lindsay Lally is a Rheumatologist in New York, New York. Dr. Lally has been practicing medicine for over 17 years is highly rated in 19 conditions, according to our data. Her top areas of expertise are Rhizomelic Pseudopolyarthritis, Polymyalgia Rheumatica, Giant Cell Arteritis (GCA), and Temporal Arteritis.

Expertise in
19
conditions
Dr. Sergio Schwartzman
Rheumatology
Expertise in
19
conditions
Dr. Sergio Schwartzman
Rheumatology
535 E 70th St, 
New York, NY 
 (5.2 mi)
212-606-1557
Languages Spoken:
English
See accepted insurances

Sergio Schwartzman is a Rheumatologist in New York, New York. Dr. Schwartzman is highly rated in 19 conditions, according to our data. His top areas of expertise are Psoriatic Arthritis, Psoriasis, Axial Spondyloarthritis (AxSpA), and Rheumatoid Arthritis (RA).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Askanase's expertise for a condition
ConditionClose
View All 40 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile